GelSight Unveils Sleek Next Generation Mobile 3D Measurement Device to Expand into New Industries
GelSight, a pioneer in tactile imaging and sensing technology, today introduced the latest version of its GelSight Mobile™ probe, the Series 2. This new generation of GelSight’s mobile device offers a sleek form-factor that is one-third lighter and less than half the volume of its predecessor, allowing it to scan surfaces in tighter spaces, while maintaining accuracy, speed, and field of view.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005405/en/
GelSight Mobile™ Series 2 offers industry-leading, tactile measurement capabilities in a more compact, ergonomic package. (Photo: Business Wire)
GelSight’s technology enables digital tactile sensing with the sensitivity and resolution of human touch. Data captured by GelSight’s elastomeric tactile sensing platform leverages proprietary software and algorithms to provide detailed, accurate surface characterization that can generate significant gains in productivity both on the production floor and in the field while also reducing the costs associated with manual or tool-based visual inspection. The handheld GelSight Mobile device can be deployed on production and assembly lines to enable rapid and well documented quality assurance decisions. Dimensions of scratches, dents, hits, gaps, offset, hole diameter, and fastener flushness can be measured in high-resolution, on any surface, in seconds.
The Series 2 head size has been minimized, so it can be utilized across a wider variety of applications. This is especially critical in the automotive and aerospace industries where it can provide rapid, repeatable, non-destructive testing for manufacturing and maintenance, repair, and overhaul (MRO) of engines, fuselages, and other critical components.
The Series 2 product addresses needs in new market verticals and creates new use cases as customers experience its game-changing performance first-hand. After bringing on new CEO, Youssef Benmokhtar, in June 2021, GelSight has set its sights on industries that can benefit from fast, accurate, micron-level measurements on a wide variety of surfaces, such as the additive manufacturing and energy sectors. The company will also continue to grow its core business in automotive, aerospace, and forensics.
“We took the accuracy, speed and mobility that our customers loved about the first-generation handheld device, and incorporated that into a smaller, more user-friendly form-factor that can deliver payback value in a matter of weeks in terms of saved production time, labor costs, and scrap,” said Youssef Benmokhtar, CEO, GelSight. “The introduction of Series 2 is ushering GelSight into a new era. We are digitizing tactile sensing to unlock new opportunities for in-line and off-line quality control innovation, across industries.”
“We use the GelSight Mobile for our MRO operations, and we are delighted to now incorporate the Mobile Series 2,” said Yann Siehen of Safran Helicopter Engines. “We had the opportunity to evaluate Series 2 and have been impressed by its performance. Its compact and lightweight design will definitely increase the number of use cases and will accelerate our return on investment.”
GelSight will be demoing the new device at the 2021 NBAA Business Aviation Convention & Exhibition (NBAA-BACE) October 12-14, 2021, in Las Vegas, NV at Booth #1224 – West Hall. To schedule a meeting and demo, please reach out to email@example.com.
The GelSight Mobile Series 2 is shipping now. To learn more about demo evaluations or purchasing, please email firstname.lastname@example.org.
To learn more about GelSight, please visit https://gelsight.com/.
GelSight develops portable, non-destructive elastomeric 3D imaging systems used to improve quality control processes in aerospace, automotive and other high-value industries. The proprietary technology that was invented at the Massachusetts Institute of Technology provides extremely detailed and rapid surface measurements and robotic sensing capabilities. For more information, please visit https://gelsight.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Kalyn Schieffer for GelSight
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
X-Chem Acquires ComInnex25.10.2021 20:00:00 CEST | Press release
X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery. With demand for high-quality discovery services increasing across the world, this complementary pairing of a North American leader in DEL and medicinal chemistry with a European leader in synthetic chemistry and custom DEL services delivers the capacity, footprint and expertise to better serve the demands of customers in a global market. “As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide,” noted Matt Clark, Ph.D., CEO of X-Chem. “The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help bio
European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-1925.10.2021 16:30:00 CEST | Press release
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the European Commission identified lenzilumab as one of the “10 most promising treatments for COVID-19” in a report and press release issued on October 22, 2021.1,2 “We are gratified the European Commission has recognized the potential of lenzilumab to offer an important treatment option for patients hospitalized with COVID-19,” said Cameron Durrant, MD, Chairman and CEO, Humanigen. “We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19. We are also progressing with our early access program, under compassionate use, where allowed by regulations in some European countries and the United States.” *Lenzilumab is not authorized, or approved
Study Finds Overwhelming Evidence That Color Blindness Hinders Learning in School, Reports EnChroma25.10.2021 14:00:00 CEST | Press release
EnChroma – creators of glasses for color blindness – today released the results of a landmark study that clearly demonstrates the negative effect color blindness has on learning for millions of students. The data strongly indicates that schools are failing to identify color blind students and that parents, educators and legislators need to better support these students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005173/en/ Standard Color Vision and Color Blind View @EnChroma In early 2020, nearly 1,000 color blind people, including the parents of color blind children, shared their opinions about how Color Vision Deficiency (CVD) affected their educational experiences. Seventy-eight percent said they were often frustrated or confused by colors in school assignments and activities. One in three say color blindness affected their confidence in school, and 30% felt like they might be a “slow learner” before discovering
Rockefeller Capital Management to Open First International Office in London with the Formation of Rockefeller Asset Management International25.10.2021 14:00:00 CEST | Press release
Rockefeller Asset Management (RAM), a division of Rockefeller Capital Management, with a long track record of investing in global equities and ESG investing has announced the formation of Rockefeller Asset Management International, to expand its European market presence. The initial plans for expansion include opening an office in London, to better serve clients across the UK, Europe, and Asia. “Our Asset Management business has generated real momentum across Europe and we are excited to continue to serve our international clients with a full suite of sustainable investment products and a growing local presence,” said Greg Fleming, CEO and President of Rockefeller Capital Management. RAM, which was recently awarded the 2021 Principles for Responsible Investing (PRI) award for “ESG incorporation initiative of the year,” has seen strong growth in Europe. Over the last two years, the business, which surpassed $2.5 billion in assets from European investors, launched a UCITS ICAV, an Irelan
Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 202125.10.2021 14:00:00 CEST | Press release
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress. One analysis evaluated the safety and efficacy of investigational RBX2660 among a broad cohort of CDI patients with comorbidities commonly found in patients with CDI, and was recognized with a Presidential Poster Award for high-quality, novel, unique and interesting research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005099/en/ Ferring Fact Sheet While the eligibility criteria in prospective clinical trials often are narrowly defined to include patients diagnosed with only CDI, this analysis allowed researchers to evaluate the impact of RBX2660 in a patient population that is more reflective of a real-world setting. In the analysis, 94 participants with comorbid conditions commonly found in people with recurrent CDI (rCDI) were trea
CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention25.10.2021 13:53:00 CEST | Press release
Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the US NIH. This new project is a major boost for the CAP256 antibody as a potential tool in the fight against HIV in Africa and showcases the potential of African researchers to fight the continent’s high-burden diseases. The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden. CAP256, isolated from a South African woman by CAPRISA and the VRC, has demonstrated a good safety profile in Phase I studies. The next step is t
Everbridge Awarded Contract to Power Countrywide Public Warning System in The Netherlands25.10.2021 13:30:00 CEST | Press release
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced that the Netherlands selected the company’s end-to-end countrywide Public Warning solution to help keep its residents and visitors safe and informed in the event of an emergency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005296/en/ Everbridge Awarded Contract to Power Countrywide Public Warning System in The Netherlands (Photo: Business Wire) One of the most densely populated regions in Europe, 17.5 million residents call the Netherlands home, and millions of tourists visit the coastal country each year. Powered by Everbridge, NL-Alert can reach 94 percent of the Dutch population on their mobile phones, along with digital signage at bus, train, tram, and metro stations across the country. The Netherlands will leverage Everbridge’s next-generation, end-to-end Public Warning solution, featuring a unique multi-chann
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom